What Are tDCS and TMS?
Neuromodulation Treatment
Overview DiagramTranscranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) are non-invasive brain stimulation techniques that modulate cortical excitability to treat chronic pain. For patients with chronic myofascial pain syndrome (myofascial pain) who have developed central sensitization, these techniques offer the ability to directly target maladaptive pain processing in the brain — effectively working to “reset” the overactive central nervous system circuits that maintain pain even after peripheral triggers have been addressed.
tDCS works by delivering a weak direct current (1–2 milliamps) through electrodes placed on the scalp. This current flows through the brain tissue between the two electrodes, shifting the resting membrane potential of neurons in the stimulated region. It does not directly cause neurons to fire — instead, it makes them more or less likely to fire in response to their normal inputs, a process called subthreshold neuromodulation.
TMS uses a coil placed against the scalp to generate rapidly changing magnetic fields that pass through the skull and induce electrical currents directly in the underlying cortical tissue. Unlike tDCS, TMS is suprathreshold — it directly causes neurons to fire action potentials. When delivered repetitively (rTMS), these induced activations produce lasting changes in cortical excitability and connectivity that outlast the stimulation period by hours, days, or even weeks.
Neuromodulation is thought to modulate the nervous system's pain processing pathways at the spinal cord level, rather than acting purely as a symptomatic blocker.
Both techniques primarily target two brain regions for pain treatment: the primary motor cortex (M1) and the dorsolateral prefrontal cortex (DLPFC). Stimulation of M1 activates descending inhibitory pain pathways that project from the cortex to the brainstem periaqueductal gray and rostral ventromedial medulla, ultimately suppressing nociceptive signaling at the spinal cord level. DLPFC stimulation modulates the emotional and cognitive dimensions of pain and is particularly useful when pain is accompanied by depression or anxiety.
Key distinction: tDCS modulates neuronal excitability without directly causing action potentials (subthreshold). TMS directly induces neuronal firing through electromagnetic induction (suprathreshold). Both produce lasting after-effects through synaptic plasticity mechanisms similar to long-term potentiation (LTP) and long-term depression (LTD).
Transcranial Direct Current Stimulation (tDCS)
How tDCS Works
tDCS delivers a constant, low-amplitude direct current between two scalp electrodes — an anode (positive) and a cathode (negative). The current (typically 1–2 mA) flows from the anode through the scalp, skull, cerebrospinal fluid, and cortical tissue to the cathode, following the path of least resistance. Approximately 50% of the applied current reaches the cortical surface.
The physiological effects depend on the polarity of stimulation relative to the underlying neurons:
Anodal Stimulation
- Depolarizes the resting membrane potential of neurons under the electrode
- Shifts neurons closer to their firing threshold
- Increases cortical excitability in the stimulated region
- Enhances spontaneous neuronal firing rates
- After-effects mediated by NMDA receptor-dependent plasticity (similar to LTP)
- Effects persist 60–90 minutes after a single 20-minute session
Cathodal Stimulation
- Hyperpolarizes the resting membrane potential of neurons under the electrode
- Moves neurons further from their firing threshold
- Decreases cortical excitability in the stimulated region
- Reduces spontaneous neuronal firing rates
- After-effects involve NMDA and GABA-dependent mechanisms (similar to LTD)
- Used primarily as the reference electrode in pain protocols
For pain treatment: Anodal tDCS over the primary motor cortex (M1) contralateral to the pain side is the standard approach. Increasing M1 excitability activates cortico-thalamic and cortico-brainstem circuits that engage the descending pain inhibitory system — projecting to the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) — which suppresses nociceptive transmission at the dorsal horn of the spinal cord.
Stimulation Parameters
Current Intensity
1–2 mAThe amplitude of direct current delivered through the scalp electrodes. Most clinical protocols use 2 mA for pain applications. Current is ramped up over 10–30 seconds at the start and ramped down at the end to minimize transient sensations such as phosphenes or skin tingling.
Session Duration
20–30 minutesEach stimulation session typically lasts 20 minutes, though some protocols extend to 30 minutes. Duration influences the magnitude and persistence of after-effects — longer stimulation produces more sustained changes in cortical excitability.
Electrode Size
25–35 cm²Standard sponge electrodes measure 5 x 5 cm (25 cm²) or 5 x 7 cm (35 cm²). Electrode size determines current density — smaller electrodes concentrate current over a smaller area, producing more focal stimulation. Sponge electrodes are soaked in normal saline (0.9% NaCl) to ensure good electrical contact with the scalp.
Electrode Placement (Pain)
Anode over M1, Cathode over contralateral supraorbital areaFor pain treatment, the anode (positive electrode) is placed over the primary motor cortex (M1) contralateral to the side of pain. The cathode (negative, reference electrode) is typically placed over the contralateral supraorbital area (above the eyebrow). This montage is designated C3/Fp2 or C4/Fp1 in the international 10–20 EEG system.
Treatment Protocol
5–10 daily sessions, then 2–3x/week maintenanceThe standard induction protocol consists of daily stimulation for 5 consecutive days (Monday through Friday), often extended to 10 consecutive weekday sessions. After the induction phase, maintenance sessions are delivered 2–3 times per week for several weeks. The cumulative effect of repeated sessions produces longer-lasting pain relief than single sessions.
Electrode Preparation
Saline-soaked sponge electrodesSponge electrode pockets are saturated with approximately 6–8 mL of normal saline per electrode. The scalp area should be clean and free of excessive hair product. Some protocols use conductive electrode gel instead of saline. Proper electrode contact is essential — high impedance from dry or poorly placed electrodes can cause skin irritation and reduce stimulation efficacy.
Key Clinical Evidence
Demonstrated that five consecutive days of anodal tDCS over M1 at 2 mA for 20 minutes produced significant and cumulative reductions in chronic pain intensity in patients with central pain, fibromyalgia, and traumatic spinal cord injury. Pain relief persisted for 2 weeks after the last stimulation session. Sham stimulation produced no significant effect.
Investigated anodal tDCS over M1 in patients with fibromyalgia. Five sessions of 2 mA tDCS for 20 minutes significantly reduced pain intensity and improved quality-of-life scores compared to sham. The analgesic effect was associated with changes in intracortical inhibition and facilitation measured by paired-pulse TMS, suggesting normalization of abnormal cortical excitability.
Conducted a systematic review and meta-analysis of tDCS for chronic pain. The pooled analysis demonstrated a statistically significant analgesic effect of anodal M1 tDCS compared to sham across multiple chronic pain conditions. The effect size was moderate, and the authors concluded that tDCS represents a promising non-pharmacological approach for chronic pain management.
Ten sessions of anodal tDCS over M1 in fibromyalgia patients produced significant improvements in pain, depression, anxiety, and quality of life. Benefits lasted for 60 days after treatment completion, suggesting that repeated tDCS sessions induce long-lasting plasticity changes in pain processing networks.
Randomized controlled trial examining tDCS for chronic nonspecific low back pain. Anodal tDCS over M1 combined with exercise produced greater pain reduction than exercise alone. This study is particularly relevant to Myofascial Pain Syndrome given the high prevalence of trigger points in chronic low back pain.
Evidence Summary for myofascial pain
Direct studies of tDCS specifically for myofascial pain syndrome are limited. However, the evidence base for fibromyalgia (which shares significant pathophysiological overlap with chronic myofascial pain through central sensitization) is moderate and growing. Evidence for chronic musculoskeletal pain broadly is also supportive. The mechanism of action — enhancing descending inhibition to counter central sensitization — is directly relevant to chronic myofascial pain.
Side Effects & Safety
| Side Effect | Frequency | Severity |
|---|---|---|
| Tingling/itching under electrodes | Very common | Mild |
| Skin redness at electrode sites | Common | Mild |
| Mild headache | Occasional | Mild |
| Fatigue | Occasional | Mild |
| Nausea | Rare | Mild |
| Skin burns (improper use) | Very rare | Moderate |
tDCS has an extremely favorable safety profile. No serious adverse events have been reported in research studies using standard parameters (up to 2 mA, up to 30 minutes). Skin burns are possible only with improper electrode preparation (dry electrodes, excessive impedance) or non-standard protocols. tDCS does not induce seizures at standard parameters.
Home-Use tDCS Devices
Several commercially available tDCS devices are marketed for home use, typically priced between $200 and $400. These devices are generally well-engineered with built-in safety features including current limiters, impedance monitors, automatic shut-off timers, and gradual ramp-up/ramp-down functions.
However, home use raises several practical concerns: optimal electrode placement requires knowledge of the 10–20 system and consistent positioning across sessions; electrode preparation (saline saturation, skin contact) directly affects stimulation quality; and the optimal treatment protocol for myofascial pain specifically is still being established. Working with a clinician to establish the initial protocol and electrode positions, then transitioning to supervised home use, is the most prudent approach.
Transcranial Magnetic Stimulation (TMS)
How TMS Works
TMS uses a coil of wire placed against the scalp to generate brief, powerful magnetic field pulses. When electrical current flows through the coil, it produces a rapidly changing magnetic field (up to 2–3 Tesla — comparable to an MRI scanner) that passes painlessly through the scalp and skull. According to Faraday’s law of electromagnetic induction, this changing magnetic field induces electrical currents in the underlying cortical tissue, directly depolarizing neurons and triggering action potentials.
Single TMS pulses are used diagnostically to map cortical function and measure motor thresholds. For therapeutic applications, repetitive TMS (rTMS) delivers trains of pulses at specific frequencies. The frequency of stimulation determines the direction of the lasting after-effects:
High-Frequency rTMS (5–20 Hz)
- Increases cortical excitability
- Induces LTP-like synaptic plasticity
- Used for pain treatment (M1 target)
- Standard for depression (DLPFC target)
Low-Frequency rTMS (1 Hz)
- Decreases cortical excitability
- Induces LTD-like synaptic plasticity
- Sometimes used over contralateral cortex
- Can be combined with HF-rTMS protocols
For chronic pain, the standard protocol involves high-frequency rTMS (typically 10 Hz) over the primary motor cortex (M1) contralateral to the side of pain. This increases M1 excitability, which activates descending inhibitory pathways projecting to the brainstem and spinal cord, suppressing nociceptive transmission. The analgesic effect builds cumulatively over repeated daily sessions and can persist for weeks to months after the treatment course ends.
Stimulation Parameters
Stimulation Frequency
5–20 Hz (high frequency)High-frequency repetitive TMS (HF-rTMS) at 5–20 Hz over the primary motor cortex is the standard protocol for pain treatment. The most common frequency used is 10 Hz. High-frequency stimulation increases cortical excitability at the target site, activating descending pain inhibitory pathways. Low-frequency rTMS (1 Hz) is sometimes used over the contralateral hemisphere for inhibitory effects.
Stimulation Intensity
80–120% of resting motor thresholdIntensity is calibrated relative to each patient's resting motor threshold (RMT) — the minimum TMS intensity required to produce a visible muscle twitch in a target hand muscle (usually the abductor pollicis brevis) in at least 5 out of 10 stimulations. Pain protocols typically use 80–90% RMT for safety, though some use up to 120% RMT. Motor threshold varies between individuals and must be determined at the beginning of each treatment course.
Pulse Count
1,000–3,000 pulses per sessionThe total number of magnetic pulses delivered per session. A typical protocol delivers 1,500–2,000 pulses. Pulses are grouped into trains (e.g., 10 seconds of 10 Hz stimulation = 100 pulses per train) separated by inter-train intervals (e.g., 50 seconds). Higher pulse counts may produce stronger effects but also increase the theoretical risk of adverse events.
Coil Type
Figure-of-eight coilThe figure-of-eight (or butterfly) coil consists of two circular windings placed side by side. The magnetic fields from each coil summate at the junction, producing a focused stimulation zone approximately 1–2 cm² at the cortical surface. This focal stimulation allows precise targeting of the primary motor cortex hand area (M1). Deep TMS using H-coils can reach deeper brain structures but with less spatial specificity.
Treatment Protocol
10–20 daily sessions over 2–4 weeksThe standard treatment course consists of daily sessions (Monday through Friday) for 2–4 weeks, totaling 10–20 sessions. Maintenance protocols following the initial course vary — some involve weekly sessions for several months, others taper gradually. The cumulative effect of repeated sessions is critical; single sessions typically produce only transient pain relief lasting hours to days.
Targeting Method
Neuronavigation or 10–20 EEG systemThe M1 target is localized using either the international 10–20 EEG system (positioning the coil 5 cm lateral to the vertex along the interaural line) or, more precisely, using frameless stereotactic neuronavigation based on the patient's structural MRI scan. Neuronavigation provides superior accuracy but requires additional equipment and expertise. The hand area of M1 is the primary target for pain applications.
Key Clinical Evidence
Comprehensive meta-analysis and evidence-based guidelines on therapeutic rTMS. High-frequency rTMS of M1 contralateral to pain received a Level A recommendation (definite efficacy) for neuropathic pain. The DLPFC target received Level B (probable efficacy) for fibromyalgia. This remains the most authoritative guideline document for clinical rTMS in pain management.
Fourteen sessions of 10 Hz rTMS over the left M1 in fibromyalgia patients produced significant and sustained reductions in pain intensity, with benefits persisting for at least 25 weeks after treatment completion. Responders showed normalization of intracortical inhibition deficits, suggesting that rTMS corrects the cortical excitability abnormalities underlying central sensitization.
Ten daily sessions of high-frequency rTMS over M1 in fibromyalgia patients significantly reduced pain and improved quality of life. The analgesic effect was observed by the fifth session and continued to improve throughout the treatment course, persisting for 2 weeks after the last session.
rTMS of the left DLPFC in fibromyalgia patients produced significant reductions in both pain and depressive symptoms. This dual effect highlights the potential of DLPFC-targeted stimulation for myofascial pain patients with comorbid mood disorders, a common clinical presentation.
High-frequency rTMS over M1 produced significant acute analgesic effects in patients with chronic myofascial pain of the jaw muscles (temporomandibular disorder). This is one of the few studies directly examining TMS in a myofascial pain population, demonstrating feasibility and analgesic efficacy.
Evidence Summary for myofascial pain
Direct evidence for TMS in myofascial pain syndrome is limited to a small number of studies (e.g., Leung et al. for TMD-related myofascial pain). However, the robust evidence from fibromyalgia trials is highly relevant given the shared central sensitization pathophysiology. Lefaucheur et al.’s Level A recommendation for M1 rTMS in neuropathic pain provides the strongest evidence base for this stimulation target.
Side Effects & Safety
| Side Effect | Frequency | Severity |
|---|---|---|
| Scalp discomfort during stimulation | Very common | Mild |
| Headache after session | Common | Mild–Moderate |
| Facial twitching during stimulation | Common | Mild |
| Lightheadedness | Occasional | Mild |
| Tinnitus | Rare | Mild |
| Seizure | Very rare | Serious |
FDA Clearance Status
TMS has received FDA clearance for several indications: treatment-resistant major depressive disorder (2008), acute migraine with aura (2013), obsessive-compulsive disorder (2018), and smoking cessation (2020). It is used off-label for chronic pain, though several clinical trials are actively pursuing pain-specific FDA clearance.
The distinction between FDA clearance and clinical evidence is important: the lack of specific FDA clearance for pain does not reflect a lack of evidence, but rather the regulatory pathway and commercial incentives. The clinical evidence supporting M1 rTMS for neuropathic pain is graded Level A (definite efficacy) by the international expert panel of Lefaucheur et al.
tDCS vs TMS — Head-to-Head Comparison
tDCS vs TMS
Head-to-Head Comparison| Feature | tDCS | TMS | Edge |
|---|---|---|---|
| Cost | $200–400 for home devices; $50–100 per clinic session | $5,000–10,000+ per treatment course; $200–500 per session | tDCS |
| Portability | Highly portable — battery-powered devices weigh <500g, can be used at home | Not portable — requires heavy equipment (50–100 kg), clinical setting only | tDCS |
| Evidence Level | Moderate — multiple RCTs, growing meta-analytic support, Level B recommendation | Strong — Level A recommendation for neuropathic pain, extensive RCT evidence | TMS |
| Mechanism | Subthreshold modulation of resting membrane potential — shifts neuronal excitability without directly causing action potentials | Suprathreshold stimulation — directly induces neuronal action potentials through electromagnetic induction | Neutral |
| Focality | Low — current spreads diffusely across a large cortical area under the electrode | High — figure-of-eight coil stimulates a focal area of approximately 1–2 cm² | TMS |
| Side Effects | Very mild — tingling, itching, skin redness. Extremely safe profile. | Mild to moderate — headache, scalp discomfort. Rare seizure risk. | tDCS |
| Session Duration | 20–30 minutes of active stimulation | 20–40 minutes including setup and motor threshold determination | Neutral |
| Accessibility | Home use possible with commercial devices; minimal training required | Requires trained clinical operator, specialized facility, and expensive equipment | tDCS |
| FDA Status | Not FDA-cleared for any indication (as of 2025); used off-label | FDA-cleared for depression (2008), migraine (2013), OCD (2018); off-label for pain | TMS |
Bottom line: tDCS wins on accessibility, cost, and safety. TMS wins on evidence strength, focality, and established clinical pathways. For patients who can access a TMS clinic and afford the treatment, TMS offers stronger evidence. For patients seeking an accessible, home-based option, tDCS is more practical. Both are reasonable options for chronic Myofascial Pain Syndrome with central sensitization.
When Brain Stimulation Makes Sense for myofascial pain
Transcranial neuromodulation is not a first-line treatment for myofascial pain. It occupies a specific role in the treatment hierarchy — targeting the central nervous system component of pain when peripheral treatments alone are insufficient. The following clinical scenarios represent the strongest indications.
Central Sensitization Is Present
Widespread pain that extends beyond the territory of identifiable trigger points, allodynia (pain from normally non-painful stimuli), hyperalgesia, and exaggerated temporal summation all suggest central sensitization. Brain stimulation directly targets the cortical processing abnormalities that maintain these features.
Peripheral Treatments Have Been Exhausted
When a comprehensive trial of peripheral interventions — including dry needling, trigger point injections, manual therapy, stretching programs, and physical therapy — has produced insufficient relief, the pain driver may have shifted from peripheral trigger points to central nervous system dysfunction requiring brain-level intervention.
Comorbid Depression or Anxiety
A substantial proportion of chronic myofascial pain patients have comorbid mood disorders. tDCS and TMS can be targeted at the dorsolateral prefrontal cortex (DLPFC) to simultaneously address both pain and mood. rTMS over the left DLPFC is FDA-cleared for treatment-resistant depression and produces parallel improvements in pain.
Chronic Duration with Nociplastic Features
Pain persisting beyond 6 months with features suggesting nociplastic pain — fatigue, sleep disturbance, cognitive difficulties, multisensory sensitivity — indicates neural remodeling that warrants brain-level treatment. The longer the chronicity, the more likely central mechanisms are maintaining the pain.
Widespread Pain Distribution
Myofascial pain that has progressed from localized trigger points to widespread body pain often reflects transition from a peripheral to a centrally maintained pain state. Patients who initially had focal trigger points but now have bilateral, multi-regional pain may benefit from cortical neuromodulation.
NOT Appropriate For
- ×Acute myofascial pain with clearly identifiable, localized trigger points (< 3 months)
- ×First-line treatment before peripheral approaches have been attempted
- ×Patients with metallic implants near the stimulation site (TMS contraindication)
- ×Patients with epilepsy or seizure history (relative TMS contraindication)
- ×When the primary pain generator is clearly peripheral and responsive to local treatment
- ×Patients with cardiac pacemakers or other implanted electronic devices (TMS)
Central Sensitization — What Patients Should Know
Neuromodulation
Central SensitizationThis section explains central sensitization in patient-friendly terms — and why brain stimulation can help chronic myofascial pain.
In normal pain processing, pain signals travel from the injured tissue through nerves to the spinal cord, and then up to the brain, where the signal is interpreted as pain. The brain also sends signals back down to the spinal cord that can either amplify or suppress incoming pain signals — like a volume control for pain.
In chronic myofascial pain syndrome, when trigger points send persistent pain signals over weeks and months, the nervous system can undergo a maladaptive change called central sensitization. The spinal cord neurons that relay pain become hyperexcitable — they start amplifying normal signals and treating non-painful inputs (like light touch or pressure) as painful. Simultaneously, the brain’s “volume down” mechanism (descending inhibition) weakens, so it can no longer effectively suppress the amplified signals.
The result is a pain processing system that is “turned up” at the spinal cord and “turned down” at the brain. Pain becomes more widespread, more intense, and more persistent than the underlying tissue injury warrants. At this stage, the pain has partly disconnected from the original trigger points — it is being maintained by the nervous system itself.
This is where brain stimulation enters the picture. tDCS and TMS target the brain’s motor cortex to strengthen the descending inhibitory pathways — essentially turning the brain’s “volume down” mechanism back on. By restoring the balance between pain amplification and pain suppression, these techniques can reduce the contribution of central sensitization to the overall pain experience.
Normal Pain
Pain proportional to tissue injury. Brain inhibition working normally.
Central Sensitization
Pain amplified at spinal cord. Brain inhibition weakened.
After Neuromodulation
Brain inhibition restored. Pain volume turned back down.
tDCS — Anodal Stimulation
Applies weak direct current (1-2 mA) via scalp electrodes to depolarize cortical neurons in the primary motor cortex (M1), increasing descending inhibition of spinal pain circuits and raising pain thresholds.
tDCS — Cathodal Stimulation
Hyperpolarizes cortical neurons in targeted regions, reducing hyperexcitability in areas like the somatosensory cortex that amplify pain signals in central sensitization states.
rTMS — High Frequency
Delivers repetitive magnetic pulses (5-20 Hz) to M1, inducing long-term potentiation-like plasticity that strengthens cortical-to-brainstem pain inhibition pathways for weeks after stimulation ends.
rTMS — Low Frequency
Applies 1 Hz stimulation to reduce cortical excitability in pain-processing regions, particularly effective for patients with central sensitization and widespread hyperalgesia.
Key Takeaways
- 1
tDCS and TMS are non-invasive brain stimulation techniques that modulate cortical excitability and activate descending pain inhibitory pathways — they treat pain at the brain level rather than at the muscle.
- 2
For chronic myofascial pain with central sensitization, these techniques can address the maladaptive neural plasticity that maintains pain even after peripheral triggers have been treated.
- 3
tDCS is inexpensive, portable, and can be self-administered at home, making it an accessible option. TMS delivers stronger and more focal stimulation but requires clinical visits and is significantly more expensive.
- 4
The strongest evidence for both techniques comes from fibromyalgia and neuropathic pain studies. Direct evidence in myofascial pain is limited but promising, given the significant pathophysiological overlap between chronic myofascial pain with central sensitization and fibromyalgia.
- 5
Brain stimulation is not a first-line treatment for myofascial pain. It is most appropriate when peripheral treatments have been inadequate, pain has become widespread, and features of central sensitization or nociplastic pain are present.
- 6
Both techniques have favorable safety profiles. tDCS side effects are limited to mild skin sensations and headache. TMS carries a very small seizure risk that is mitigated by proper screening and adherence to safety guidelines.
- 7
Combining brain stimulation with peripheral treatments (exercise, manual therapy, needling) and psychological approaches (CBT, pain education) is likely to produce the best outcomes — addressing both central and peripheral pain mechanisms simultaneously.
- 8
Ongoing trials are testing optimal parameters, patient-selection criteria, and combination protocols.